Todos Medical Ltd (OTCMKTS:TOMDF) Stock In Downtrend: Falls 22% In a Week

Todos Medical Ltd (OTCMKTS: TOMDF) fell 13% and 22% in a week. The company has announced that its CEO and PRESIDENT Gerald Commission will present at the upcoming Emerging Growth Conference taking place on January 5, 2022.

Market Stats

On Monday, TOMDF stock slid 12.75% to $0.0510 with more than 12.37 million shares, compared to its average volume of 10.35 million shares. The stock has moved within a range of $0.0490 – 0.0600 after opening trading at $0.0514.

Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

Recently the company revealed that its automated CLIA/CAP PCR and cPass neutralizing COVID-19 antibody testing lab Provista Diagnostics attained consecutive weekly COVID PCR testing volumes from December 13, 2021, through December 20, 2021. COVID PCR testing numbers were driven mainly by reference laboratory activity from a New York-based PCR testing facility that could not meet testing demand at its current location.

A new laboratory services agreement for COVID PCR Testing and COVID cPass neutralizing antibody test was also signed with a New Jersey-based physician practice. Commisiong said that PCR testing demand is increasing in parts of the US and the trend is likely to continue past the holiday with schools, employers, and schools seeking to create safe conditions in areas with low vaccinations rates. So in the coming weeks, TOMDF is worth watching.

Key Quote

“The demand for PCR testing is rapidly increasing in pockets of the United States, and we expect this to continue beyond the holiday surge as individuals, schools and employers seek to create safe environments, especially in areas with low vaccination rates,” said Gerald E. Commissiong, President & CEO of Todos Medical, the parent company of Provista Diagnostics.

Traders Corner

TOMDF stock is below the 20-Day and 50-Day Moving averages of $0.0617 and $0.0550 respectively. The stock is trading in the neutral zone with the RSI at 41.